Advertisement

Topics

Exclusive: Novartis pitches discounts on pricey gene therapy for deadly muscle disorder

09:40 EDT 10 May 2019 | Reuters

Novartis AG is offering price discounts in negotiations with U.S. health insurers on its gene therapy for spinal muscular atrophy (SMA), a treatment that could cost more than a million dollars, but the gesture comes with strings attached.

Original Article: Exclusive: Novartis pitches discounts on pricey gene therapy for deadly muscle disorder

NEXT ARTICLE

More From BioPortfolio on "Exclusive: Novartis pitches discounts on pricey gene therapy for deadly muscle disorder"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Novartis
Novartis is the fourth largest pharmaceutical company in the world, based on annual sales, which are exceeded $36,000m in 2009. Founded in 1996, Novartis focuses of four main areas; pharmaceuticals, vaccines & diagnostics, generic medicines and biosi...

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...